RJX Platform
Vascular, Oncology, CNS, Ocular Diseases
Research/PreclinicalActive
Key Facts
Indication
Vascular, Oncology, CNS, Ocular Diseases
Phase
Research/Preclinical
Status
Active
Company
About Reven Pharmaceuticals
Reven Pharmaceuticals is a clinical-stage biotech focused on its proprietary RJX Technology, a drug platform designed to modulate the immune system and address inflammatory pathways across a broad range of diseases. The company has progressed RJX into Phase 2 clinical trials for COVID-19-related acute respiratory distress syndrome (ARDS) and sepsis, building on earlier compassionate use and a completed Phase 1 safety study. However, the company is currently embroiled in significant legal and regulatory challenges with the SEC, including an asset freeze and an ongoing court appeal, which pose a major threat to its operations and future.
View full company profile